Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 5NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Biochemical Recurrent Prostate Cancer 1

Interventions

Specimen Handling 188Magnetic Resonance Spectroscopy 143Biopsy 116Nivolumab 39X-Rays 29Immunoglobulin G 29Disulfides 29Radiation 28Carboplatin 27atezolizumab 25Taxes 25Paclitaxel 25pembrolizumab 23Radiotherapy 23Ipilimumab 23CTLA-4 Antigen 23olaparib 22Cyclophosphamide 22Cisplatin 21Platinum 20Gemcitabine 20Doxorubicin 20Bevacizumab 201,2-diaminocyclohexaneplatinum II citrate 20Phantoms, Imaging 19Vincristine 17trametinib 16cabozantinib 15Rituximab 15ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × NIH × Radium-223 × Clear all
NCT04206319 2026-03-16

Radium-223 in Biochemically Recurrent Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
19 enrolled
Genitourinary

Biochemical Recurrent Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡